OBOdile Boespflug-Tanguy

Odile Boespflug-Tanguy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Odile Boespflug-Tanguy has a total of 297 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety and effectiveness of givinostat in boys with Duchenne muscular dystrophy: a plain language summary of the EPIDYS clinical trial

    by Eugenio Mercuri, Odile Boespflug-Tanguy, Jean K. Mah, Tracey Willis, Erika L. Finanger, Carlos Ignacio Ortez González, Paolo Bettica, Chamindra G. Laverty

    (2026). Safety and effectiveness of givinostat in boys with Duchenne muscular dystrophy: a plain language summary of the EPIDYS clinical trial. Future Rare Diseases: Vol. 6, No. 1, 2719465.

  • Familial pulmonary alveolar proteinosis and type I interferonopathy by mutation of STAT2 (TIMS2)

    by Conor Gruber, Meredith Ramba, Bineeta Debnath, Lorenzo Cuollo, Anna-Lena Neehus, Angelica Lee, Sofija Buta, Marta Martin-Fernandez, Jérémie Rosain, Laureline Berteloot, et al.

    Mutations that enhance type I interferon (IFN-I) activity cause monogenic autoinflammatory disorders termed type I interferonopathies. Along with the typical neurologic and rheumatologic manifestations, severe pulmonary disease is increasingly recognized yet poorly understood. We studied three siblings presenting with early-onset, life-threatening pulmonary alveolar proteinosis (PAP) and autoinflammatory stigmata. Genetic analysis uncovered a novel homozygous variant (R223Q) in STAT2, a key mediator of IFN-I signaling, which also facilitates feedback inhibition via USP18. R223Q STAT2 preserved signal transduction and viral control in vitro. However, cells homozygous for the R223Q variant failed to terminate IFN-I responses, owing to impaired localization of USP18. Unlike in classical forms of PAP, GM-CSF signaling remained intact. Instead, persistent IFN-I signaling antagonized monocyte migration toward chemokines essential for lung trafficking. Informed by these findings, the youngest sibling received JAK inhibitor and anti-IFN-I receptor therapy with marked clinical improvement. Collectively, type I interferonopathy by mutation of STAT2 (TIMS2) compromises monocyte chemotaxis and underlies a novel mechanism of PAP.


  • Open Access

    Human TBK1 deficiency: An expanded spectrum from autoinflammation to viral encephalitis

    by Yemsratch Akalu, Justin Taft, Thomas Berger, Kevin Rostásy, Hormos S. Dafsari, Helena Schönrade, Müşerref Kasap Cüceoğlu, Seza Özen, Albert Faye, Isabelle Melki, et al.

    New and long-term follow-up cases of human TBK1 deficiency reveal that patients are vulnerable to severe viral encephalitis in addition to systemic autoinflammation. Findings underscore the dual nature of TBK1 deficiency in combining autoinflammatory disease with impaired antiviral defense.


  • Open Access

    ARSA Variants Associated With Cognitive Decline and Long‐Term Preservation of Motor Function in Metachromatic Leukodystrophy

    by Shanice Beerepoot, Daphne H. Schoenmakers, Francesca Fumagalli, Samuel Groeschel, Ludger Schöls, Raphael Schiffmann, Sheila Wong, Odile Boespflug‐Tanguy, Caroline Sevin, Yann Nadjar, et al.

    Patients with metachromatic leukodystrophy (MLD) show variable motor and cognitive decline. The ARSA variants c.256C>T, p.(Arg86Trp), c.257G>A, p.(Arg86Gln) and c.542T>G, p.(Ile181Ser) are associated with predominantly cognitive decline. This multinational study analyzed MLD onset type, presenting signs/symptoms, cognitive function, gross motor function, central motor tract involvement, MRI severity score, peripheral neuropathy, and survival of 47 patients (three homozygous for c.256C>T and five, twelve and 27 compound heterozygous for c.256C>T, c.257G>A, or c.542T>G and another ARSA variant, respectively). Eleven underwent hematopoietic stem cell transplantation (HSCT). Onset was late‐juvenile (46.8%) or adult (44.7%) with predominantly cognitive decline ( n = 40/41 symptomatic patients). At diagnosis, untreated patients typically retained independent walking (100%), sparing of central motor tracts (87.5%), and absence of demyelinating neuropathy (95.5%), which persisted in follow‐up for most (76.5%, 71.4%, and 64.7%, respectively). Early‐juvenile onset and rapid motor decline occurred only in patients compound heterozygous for c.256C>T and a severe second variant ( n = 4), showing central motor tract involvement at diagnosis. One untreated and one treated patient died of disease progression, and another from HSCT complications. All other treated patients retained independent walking, and four of five tested normal cognitive function. Median MRI severity score remained lower in treated (13) than untreated patients (25). The phenotype of c.256C>T carriers depends on the severity of the second ARSA variant. Patients harboring c.257G>A or c.542T>G show late‐juvenile or adult onset with cognitive decline and preserved motor function, usually associated with sparing of central motor tracts. In these patients, cognitive function and MRI severity score should be preferred treatment outcomes.


  • Open Access

    Acid Ceramidase Deficiency

    by Silvestre Cuinat, Paul Rollier, Katheryn Grand, Pedro A. Sanchez-Lara, Michelle Allen-Sharpley, Thierry Levade, Marie T. Vanier, Laurence Lion Francois, Nicole Chemaly, Capucine de Lattre, et al.

    Spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME) due to acid ceramidase deficiency is a rare disorder, allelic with Farber disease, resulting from recessive ASAH1 variants. Patients present in early childhood with muscle weakness due to anterior horn degeneration and/or progressive drug-resistant myoclonic epilepsy. Death usually results from respiratory complications or status epilepticus during adolescence. We identified 9 patients with SMA-PME from 5 different families followed in neurology, rehabilitation, and genetics departments of university hospitals in France and the United States. During disease progression, motor functional scores were assessed for seven of them and C26-ceramide quantification on dried blood spots (DBSs) was performed for 4 of them. An in cell assay, measuring the degradation rate of ceramides in living skin fibroblasts, was also performed in 2 patients. Finally, a literature review was conducted. Twelve years after the molecular characterization of SMA-PME, here we present the detailed history of 9 patients from 5 different families with 4 new ASAH1 variants. The prospective follow-up for 4 of them allows us to evaluate the relevance of functional scales and of C26-ceramide assay on DBS, as a biomarker. In addition, an in cell assay could provide a more reliable level of the residual ceramidase activity. Based on a comprehensive literature review, we provide a detailed description of the natural history of the 44 patients with SMA-PME diagnosed to date and show a genotype-phenotype correlation for the 2 main variants and the disease onset. This study presents the detailed natural history of SMA-PME. Given the rarity of this disease and the current lack of a reliable biomarker for patient follow-up, this work may serve as a retrospective control group for future therapeutic trials.


  • Open Access

    A biallelic variant inGORASP1causes a novel Golgipathy with glycosylation and mitotic defects

    by Sophie Lebon, Arnaud Bruneel, Séverine Drunat, Alexandra Albert, Zsolt Csaba, Monique Elmaleh, Alexandra Ntorkou, Yann Ténier, François Fenaille, Pierre Gressens, et al.

    GRASP65 is a Golgi-associated peripheral protein encoded by theGORASP1gene and required for Golgi cisternal stacking in vitro. A key role of GRASP65 in the regulation of cell division has also been suggested. However, depletion of GRASP65 in mice has little effect on the Golgi structure and the gene has not been associated with any human phenotype to date. Here, we report the identification of the first human pathogenic variant ofGORASP1(c.1170_1171del; p.Asp390Glufs*18) in a patient combining a neurodevelopmental disorder with neurosensory, neuromuscular, and skeletal abnormalities. Functional analysis revealed that the variant leads to a total absence of GRASP65. The structure of the Golgi apparatus did not show fragmentation, but glycosylation anomalies such as hyposialylation were detected. Mitosis analyses revealed an excess of prometaphases and metaphases with polar chromosomes, suggesting a delay in the cell cycle. These phenotypes were recapitulated in RPE cells in which a similar mutation was introduced by CRISPR/Cas9. These results indicate that loss of GRASP65 in humans causes a novel Golgipathy associated with defects in glycosylation and mitotic progression.


  • Open Access

    Macrophage-derived RNAseT2 stimulates muscle stem cell fusion via SLK/N-WASP/actin bundling

    by Michele Weiss-Gayet, Gaetan Juban, Emmeran Le Moal, Antonio Moretta, Camilla Farnetari, Christelle Gobet, Jules Guillemaud, Marie-Catherine Le Bihan, Oded Shoseyov, Annie Adrait, et al.

    Muscle stem cells (MuSCs) fuse to form myofibers to repair skeletal muscle after injury. Within the regenerative MuSC niche, restorative macrophages stimulate MuSC fusion, although the molecular mechanisms involved are largely unknown. Here, we show that restorative macrophages secrete ribonuclease T2 (RNAseT2) to stimulate MuSC fusion. RNAseT2 entered MuSCs via the mannose receptor and induced the formation of actin bundles in MuSCs, enabling cell/cell fusion. Mechanistically, RNAseT2 bound to Ste20-like kinase (SLK), which itself triggered the phosphorylation-mediated activation of N-WASP, through Paxillin phosphorylation, allowing actin bundling necessary for MuSC fusion. In vivo, overexpressing RNAseT2 in regenerating muscle increased fusion in newly formed myofibers in mouse and zebrafish while macrophages deficient for RNAseT2 gene led to fusion defect and smaller myofibers. This study reveals a new function for the highly conserved RNAseT2 and provides a new molecular mechanism by which restorative macrophages support MuSC fusion during muscle repair.


  • Gene therapy for neurodegenerative disorders in children: dreams and realities

    by Odile Boespflug-Tanguy, Caroline Sevin, Francoise Piguet


  • Open Access

    Questioning cognitive heterogeneity and intellectual functioning in fetal alcohol spectrum disorders from the Wechsler Intelligence Scale for Children

    by Eliot Kerdreux, Justine Fraize, Pauline Garzón, Esther Chalain, Léa Etchebarren, Delphine Sitbon, Anna Maruani, Odile Boespflug-Tanguy, Lucie Hertz-Pannier, Marion Noulhiane, et al.

    Introduction: Fetal Alcohol Spectrum Disorders (FASD) are characterized by a variety of multiple cognitive and behavioral impairments, with intellectual, attentional, and executive impairments being the most commonly reported. In populations with multiple neurodevelopmental disorders, the Full Scale Intelligence Quotient (FSIQ) may not be a proper measure of intellectual abilities, rarely interpreted in FASD clinical practice because the heterogeneity of the cognitive profile is deemed too strong. We propose a quantitative characterization of this heterogeneity, of the strengths and weaknesses profile, and a differential analysis between global cognitive (FSIQ) and elementary reasoning abilities in a large retrospective monocentric FASD sample. Methods: Using clinical and cognitive data (Wechsler Intelligence Scale for Children) from 107 children with FASD, we characterized subject heterogeneity (variance and scatter of scaled/composite scores), searched for strengths and weaknesses, and specified intellectual functioning in terms of FSIQ and elementary reasoning (General Abilities Index, Highest Reasoning Scaled Score), in comparison with standardization norms and a Monte-Carlo-simulated sample from normalization data. Results: Performance of children with FASD was lower on all subtests, with a significant weakness in working memory and processing speed. We found no increase in the variance and scatter of the scores, but a discordance between the assessment of global cognitive functioning (28% borderline, 23% deficient) and that of global and elementary reasoning abilities (23-9% borderline, 15-14% deficient). Conclusion: Our results question the notion of WISC profile heterogeneity in FASD and point to working memory and processing speed over-impairment, with global repercussions but most often preserved elementary reasoning abilities.


  • Open Access

    RINT1 deficiency disrupts lipid metabolism and underlies a complex hereditary spastic paraplegia

    by Nathalie Launay, Montserrat Ruiz, Laura Planas-Serra, Edgard Verdura, Agustí Rodríguez-Palmero, Agatha Schlüter, Leire Goicoechea, Cristina Guilera, Josefina Casas, Felix Campelo, et al.

    The Rad50 interacting protein 1 (Rint1) is a key player in vesicular trafficking between the ER and Golgi apparatus. Biallelic variants in RINT1 cause infantile-onset episodic acute liver failure (ALF). Here, we describe 3 individuals from 2 unrelated families with novel biallelic RINT1 loss-of-function variants who presented with early onset spastic paraplegia, ataxia, optic nerve hypoplasia, and dysmorphic features, broadening the previously described phenotype. Our functional and lipidomic analyses provided evidence that pathogenic RINT1 variants induce defective lipid–droplet biogenesis and profound lipid abnormalities in fibroblasts and plasma that impact both neutral lipid and phospholipid metabolism, including decreased triglycerides and diglycerides, phosphatidylcholine/phosphatidylserine ratios, and inhibited Lands cycle. Further, RINT1 mutations induced intracellular ROS production and reduced ATP synthesis, affecting mitochondria with membrane depolarization, aberrant cristae ultrastructure, and increased fission. Altogether, our results highlighted the pivotal role of RINT1 in lipid metabolism and mitochondria function, with a profound effect in central nervous system development.